Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2020

Nov 12, 2020

SELL
$3.07 - $5.0 $82,162 - $133,815
-26,763 Closed
0 $0
Q2 2020

Aug 17, 2020

BUY
$2.06 - $3.76 $55,131 - $100,628
26,763 New
26,763 $100,000

Others Institutions Holding GLYC

About GLYCOMIMETICS INC


  • Ticker GLYC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 52,423,900
  • Market Cap $14.7M
  • Description
  • GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. It is developing uproleselan, an E-selectin inhibitor, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML),...
More about GLYC
Track This Portfolio

Track Cigna Investments Inc Portfolio

Follow Cigna Investments Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cigna Investments Inc , based on Form 13F filings with the SEC.

News

Stay updated on Cigna Investments Inc with notifications on news.